A Prospective Trial to Evaluate the Role of In Vivo T Cell Depletion by Campath (Alemtuzumab) in Reduction of Transplant Related Mortality in Transplantation from HLA-Class I or Class II Mismatched, Unrelated Donors.

Trial Profile

A Prospective Trial to Evaluate the Role of In Vivo T Cell Depletion by Campath (Alemtuzumab) in Reduction of Transplant Related Mortality in Transplantation from HLA-Class I or Class II Mismatched, Unrelated Donors.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 26 May 2017

At a glance

  • Drugs Alemtuzumab (Primary) ; Busulfan; Cyclophosphamide; Tacrolimus
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic myeloid leukaemia; Graft-versus-host disease; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Jan 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 26 Aug 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 29 Oct 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top